Claims

1. A medium for neural stem cells and/or neural progenitor cells, comprising human serum albumin, fatty acid, transferrin, ethanolamine, and basic fibroblast growth factor (bFGF),

wherein the amount of the fatty acid in the medium is not more than 50 μM,

wherein the medium is a serum-free medium,

wherein the amount of the human serum albumin in the medium is not less than 0.5 mg/mL and not more than 2.1 mg/mL,

wherein the amount of bFGF in the medium is not less than 5 ng/mL and not more than 100 ng/mL,

wherein the amount of transferrin in the medium is not less than 0.5 μg/mL and not more than 10 μg/mL, and

wherein the amount of ethanolamine in the medium is not less than 5 μg/mL and not more than 50 μg/mL.

2. The medium according to claim 1, which is for maintaining undifferentiation of neural stem cells and/or neural progenitor cells.

3. The medium according to claim 1 or 2, which is for promoting proliferation of neural stem cells and/or neural progenitor cells.

4. The medium according to any one of claims 1 to 3, which is for maintaining undifferentiation of and promoting proliferation of neural stem cells and/or neural progenitor cells.

5. The medium according to any one of claims 1 to 4, wherein the neural stem cells and/or neural progenitor cells are derived from pluripotent stem cells.

6. The medium according to any one of claims 1 to 5, wherein the human serum albumin is a recombinant human serum albumin.

7. The medium according to any one of claims 1 to 5, wherein the human serum albumin is derived from human plasma.

8. The medium according to any one of claims 1 to 7, wherein the amount of the fatty acid in the medium is not more than 20 μM.

9. The medium according to any one of claims 1 to 8, which is for suspension culture.

10. A method of proliferating neural stem cells and/or neural progenitor cells, comprising adding human serum albumin, fatty acid, transferrin, ethanolamine, and bFGF to a medium,

wherein the amount of the fatty acid in the medium is not more than 50 μM,

wherein the medium is a serum-free medium,

wherein the amount of the human serum albumin in the medium is not less than 0.5 mg/mL and not more than 2.1 mg/mL,

wherein the amount of bFGF in the medium is not less than 5 ng/mL and not more than 100 ng/mL,

wherein the amount of transferrin in the medium is not less than 0.5 μg/mL and not more than 10 μg/mL, and

wherein the amount of ethanolamine in the medium is not less than 5 μg/mL and not more than 50 μg/mL.

11. A method of maintaining undifferentiation of neural stem cells and/or neural progenitor cells, comprising adding human serum albumin, fatty acid, transferrin, ethanolamine, and bFGF to a medium

wherein the amount of the fatty acid in the medium is not more than 50 μM,

wherein the medium is a serum-free medium,

wherein the amount of the human serum albumin in the medium is not less than 0.5 mg/mL and not more than 2.1 mg/mL,

wherein the amount of bFGF in the medium is not less than 5 ng/mL and not more than 100 ng/mL,

wherein the amount of transferrin in the medium is not less than 0.5 μg/mL and not more than 10 μg/mL, and

wherein the amount of ethanolamine in the medium is not less than 5 μg/mL and not more than 50 μg/mL.

12. A method of promoting proliferation of neural stem cells and/or neural progenitor cells while maintaining undifferentiation thereof, comprising adding human serum albumin, fatty acid, transferrin, ethanolamine, and bFGF to a medium

wherein the amount of the fatty acid in the medium is not more than 50 μM,

wherein the medium is a serum-free medium,

wherein the amount of the human serum albumin in the medium is not less than 0.5 mg/mL and not more than 2.1 mg/mL,

wherein the amount of bFGF in the medium is not less than 5 ng/mL and not more than 100 ng/mL,

wherein the amount of transferrin in the medium is not less than 0.5 μg/mL and not more than 10 μg/mL, and

wherein the amount of ethanolamine in the medium is not less than 5 μg/mL and not more than 50 μg/mL.

13. The method according to any one of claims 10 to 12, wherein the neural stem cells and/or neural progenitor cells are derived from pluripotent stem cells.

14. The method according to any one of claims 10 to 12,

wherein the human serum albumin is recombinant human serum albumin.

15. The method according to any one of claims 10 to 12, wherein the human serum albumin is derived from human plasma.

16. The method according to any one of claims 10 to 15, wherein the amount of the fatty acid in the medium is not more than 20 μM.

17. The method according to any one of claims 10 to 16, wherein the neural stem cells and/or neural progenitor cells are cultured in suspension in the medium.

18. A culture composition comprising the medium according to any of claims 1 to 9 and neural stem cells and/or neural progenitor cells.